Citius Pharmaceuticals, Inc. is a US-based pharmaceutical company specializing in anti-infectives, prescription products, and stem cell therapy in cancer care. With a high risk assessment ESG score of 34.9, the company is advancing four unique product candidates including LYMPHIR for cutaneous T-cell lymphoma, Mino-Lok for bloodstream infections, Mino-Wrap for tissue expander infections, Halo-Lido for hemorrhoids, and NoveCite for acute respiratory distress syndrome treatment.